美國的玻尿酸 (HA) 關節內粘稠補充療法市場:2011年∼2021年
US Market for Hyaluronic Acid Viscosupplementation 2011-2021
|出版商||iData Research Inc.||商品編碼||203687|
|出版日期||內容資訊||英文 50 Pages
|美國的玻尿酸 (HA) 關節內粘稠補充療法市場:2011年∼2021年 US Market for Hyaluronic Acid Viscosupplementation 2011-2021|
|出版日期: 2015年06月01日||內容資訊: 英文 50 Pages||
本報告提供美國的玻尿酸 (HA) 關節內粘稠補充療法市場相關調查分析、市場概要、市場分析與預測、推動因素與阻礙因素 、競爭分析相關的系統性資訊。
Viscosupplementation products are approved for direct injection into the knee to relieve pain caused by osteoarthritis. Though the active mechanism is not completely understood, the intention is to restore the shock absorbing nature of the joint fluid.
Although these products treat the symptoms of osteoarthritis and are not permanent cures, patients generally report decreased pain and an improvement in performance of daily activities. Despite the method of application, these products are classified as medical devices and not pharmaceuticals, although some claim that there are associated anti-inflammatory effects.
There are three forms of hyaluronic acid products available on the market: single-injection, three-injection and five-injection cycles. These products vary in their volumes and concentrations of sodium hyaluronate. The three-injection and five-injection products are well-established in the U.S. market. The first single-injection product was approved by the FDA in February 2009; the corresponding market has grown very rapidly.